Keep up with your IP – a global look at filing life sciences patents
The Patent Lawyer Magazine – FILING LIFE SCIENCES PATENTS ; May/June 2022 Daniel Tjoernelund and Sharon Meyer of Azami Global evaluate the filing process for
The Patent Lawyer Magazine – FILING LIFE SCIENCES PATENTS ; May/June 2022 Daniel Tjoernelund and Sharon Meyer of Azami Global evaluate the filing process for
Looking back at the past decade, in 2013, filings of patent lawsuits in the United States were at an unprecedented high, and remained that way
Australia stands apart from many other key jurisdictions in allowing first and second medical use claims drafted as “method of medical treatment” or “Swiss-form” claims.
FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas Pharma Inc. v Akebia Therapeutics Inc. and other companies [2021] EWCA Civ 1279 What are the
When evaluating the novelty of claims in life sciences and pharmaceutical, compared with EPO, the examination practice in China is more stringent when determining whether
The Canadian Patent Act imposes an unyielding relationship between the requirement for a written description of the invention and claims for which patent protection is sought. A
United States – Head Offices
82 Nassau St #60492
New York, NY 10038
__
1 North State Street
15th floor
Chicago, IL 60602
Singapore
7 Temasek Boulevard, #12-07
Suntec Tower One
Hong Kong
Tung Wai Commercial Building,
Suite 1404
109-111 Gloucester Road, Wan Chai
Copyright © 2022. All Rights Reserved.